Company intelligence / Profile preview

JelloX Biotech

Zhubei City, Hsinchu County, Taiwanjellox.com ↗

Ownership: Private
Development stage: Commercial

Overview

JelloX’s technology has demonstrated improved sensitivity in clinical studies in Japan and Taiwan for various cancers. Their AI-powered 3D pathology platform can reclassify prior false-negative cases and provide more comprehensive tumor biology insights. MetaLite® software received FDA 510(k) clearance.

Therapeutic areas: Oncology
Modalities: Digital pathology platformAntibody
Industry: Pathology

Partnerships

Collaboration with a leading US medical center for global alliance on AI-powered digital pathology developmentCollaborations with hospitals for unique tumor recognition AI models

Beyond the preview

Go deeper on JelloX Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JelloX Biotech.

Explore the full profile